RYR2 and catecholaminergic polymorphic ventricular tachycardia: Conceptually, CaMKII presents an attractive target in CPVT because its established actions at various Ca2+ handling proteins would all be expected to exacerbate arrhythmia resulting from RyR2 hyperactivity.